Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Clinical trial NCT03036488 · COMPLETED
Trial details
- NCT number
- NCT03036488
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-07
- Primary completion
- 2025-10-14
- Enrollment
- 1174
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.